Baron and Budd Now Handling Actos Lawsuits

Alert: Diabetes Drug Actos Has Allegedly Been Linked to Serious Health Problems, Including Bladder Cancer

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We are here to represent men and women who were harmed by taking a drug that was supposed to be helpful.

DALLAS (PRWEB) June 14, 2013

National plaintiffs’ law firm Baron and Budd is now handling lawsuits regarding the alleged adverse side effects of the diabetes drug Actos. Actos, also known as pioglitazone, has been prescribed since 1999 to help treat type 2 diabetes. The drug was marketed to help people control blood sugar levels with a minimum of side effects, making it a top-selling diabetes drug. However, many patients who used Actos allegedly suffered from serious health issues while taking the drug, such as bladder cancer. Baron and Budd Actos lawyers are currently working to assist people who may have experienced adverse health problems during or after taking Actos (In re: Actos Product Liability Litigation, MDL No. 2299).

“People who are ill shouldn't have to fear taking the medications their doctors prescribe,” said Russell Budd, founder and managing shareholder of Baron and Budd. “We are here to represent men and women who believe they were harmed by taking a drug that was supposed to be helpful."

The link between Actos and bladder cancer was made within the first five years of a ten-year study by Takeda Pharmaceuticals, the manufacturer of Actos. The study, conducted at the request of the Federal Drug Administration (FDA), uncovered that patients taking Actos for more than a year had a 40 percent higher risk of developing bladder cancer than patients taking other diabetes drugs. The study also found that the longer a patient took Actos, or the higher the dosage prescribed, the greater the risk of adverse health effects. ("The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study," The British Medical Journal. Published May 2012. http://www.bmj.com/content/344/bmj.e3645

In light of these findings, regulators in Canada, France and Germany suspended Actos sales. However, sales continued in the U.S., where Actos is still sold today. While the FDA has not yet pulled Actos from the market, it has issued strong warnings about its use. In 2011, the FDA published a new warning label for Actos, and recommended that doctors not prescribe Actos to patients who have or have had bladder cancer.

If you or someone you know has taken Actos and suffered serious health problems, contact our Actos lawyers today at 1.866.844.4556 or email the attorneys at info(at)baronbudd(dot)com. To learn more about Baron and Budd and Actos lawyers, visit the firm’s website here: http://baronandbudd.com/areas-of-practice/unsafe-drugs-and-medical-devices/actos-lawyer/.

The attorneys at Baron and Budd have been Protecting What’s Right for consumers for more than 35 years. Over the years, the firm has built a successful track record representing people who have been harmed by corporate wrongdoing. The firm’s pharmaceutical lawyers recently represented over 7,000 patients harmed by using the drug Avandia. The firm currently represents a number of states in litigation against manufacturer GlaxoSmithKline (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation). Previously, Baron & Budd played a prominent role in litigation related to the diet drug Fen-Phen. As a result, the case settled for an amount valued at more than $1.275 billion (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.).


Contact

  • Amanda Theaker, Marketing
    Baron & Budd
    214.991.1051
    Email